ASCO GU Conference Coverage
Filter News By:

Featured Conference News

2021 GU Cancers Symposium: RETAIN BLADDER Trial Offers Promise for Sparing Cystectomy

February 13 2021 - Active surveillance after neoadjuvant chemotherapy may someday be an option for some patients with muscle invasive bladder cancer and certain predictive genomic factors, according to interim findings reported at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium.

2021 GU Cancers Symposium: Lenvatinib Combos Improve PFS in Advanced RCC

February 13 2021 - Lenvatinib, combined with either pembrolizumab or everolimus, outperformed sunitinib monotherapy in progression-free survival (PFS) for patients with advanced renal cell carcinoma (RCC), according to findings presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium.

2021 GU Cancers Symposium: Titan Trial Shows Survival Benefit of Adding Apalutamide to ADT

February 12 2021 - Adding apalutamide to androgen deprivation therapy (ADT) significantly improved overall survival for patients with metastatic castration-sensitive prostate cancer (mCSPC) over ADT alone, according to findings reported at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium.

2021 GU Cancers Symposium: Enfortumab Vedotin Bests Chemo in Advanced Urothelial Cancer

February 12 2021 - Enfortumab vedotin (EV) outperformed chemotherapy on key survival metrics in a phase 3 trial, extending the life of patients with previously treated advanced urothelial cancer by nearly four months, compared with standard care.

2021 GU Cancers Symposium: Apalutamide Combo Boosts PFS in ACIS Trial of mCRPC

February 11 2021 - Combining apalutamide (APA) with abiraterone acetate plus prednisone (AAP) reduced the risk of radiographic progression or death by 31% in patients with advanced prostate cancer who had never received chemotherapy, according to findings presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium.

Featured News
View all
More News
(Dana-Farber) Feb 13, 2021 - Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer.
(Pharmaphorum [UK]) Feb 15, 2021 - Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.
(Exelixis) Feb 13, 2021 - Exelixis, Inc. today announced positive phase 2 results for CABOMETYX® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,1 in patients with...
(Yale Cancer Center) Feb 12, 2021 - In a new study led by researchers at Yale Cancer Center (YCC), the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced...
(Evaluate Vantage) Feb 15, 2021 - A little-noticed Merck & Co presentation at Asco-GU over the weekend should be of interest to followers of Arrowhead Pharmaceuticals. It concerns MK-6482, a HIF-2α inhibitor that now carries the INN...
(Exelixis) Feb 12, 2021 - Exelixis, Inc. today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozantinib in combination...
(ICR [UK]) Feb 12, 2021 - Men who have had treatment for early stage testicular cancer could benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging,...
(Yahoo! Finance) Feb 16, 2021 - ImmunityBio, Inc. today announced the oral presentation of "Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in...
(OBR) Feb 13, 2021 - Lenvatinib, combined with either pembrolizumab or everolimus, outperformed sunitinib monotherapy in progression-free survival (PFS) for patients with advanced renal cell carcinoma (RCC), according to findings presented...
(OBR) Feb 13, 2021 - Active surveillance after neoadjuvant chemotherapy may someday be an option for some patients with muscle invasive bladder cancer and certain predictive genomic factors, according to interim findings reported at the...

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj